COVFIS2021: Efficacy of Respiratory Rehabilitation After COVID-19 Severe Infection

Sponsor
Institut d'Investigació Biomèdica de Girona Dr. Josep Trueta (Other)
Overall Status
Recruiting
CT.gov ID
NCT05307562
Collaborator
(none)
108
1
2
51.7
2.1

Study Details

Study Description

Brief Summary

The purpose of this study is to investigate the effects of a training program in patients that have suffered a COVID infection

Condition or Disease Intervention/Treatment Phase
  • Other: Interval training + analytical strength
  • Other: Interval training + analytical strength and IMT
N/A

Detailed Description

Once patients have been selected and meet inclusion criteria, they will sign informed consent. They will make a first visit to obtain the basal parameters. Once done, they will start the individualized training program for 12 weeks 3 times a week.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
108 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Double (Investigator, Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
Efficacy of Respiratory Rehabilitation After COVID-19 Severe Infection
Actual Study Start Date :
Aug 10, 2021
Anticipated Primary Completion Date :
Apr 1, 2025
Anticipated Study Completion Date :
Dec 1, 2025

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Training program

Global intervallic exercise using cyclometer and analytical strength exercises

Other: Interval training + analytical strength
Patients will receive a training program

Experimental: Training program + Inspiratory muscle traioning (IMT)

Global intervallic exercise using cyclometer and analytical strength exercises + inspiratory muscles training

Other: Interval training + analytical strength and IMT
Patients will receive a training program + IMT

Outcome Measures

Primary Outcome Measures

  1. changes in walking distance in the 6 minutes walk test [Baseline and 12 weeks after]

    6MWT is a submaximal test performed in 30 meters corridor.

Secondary Outcome Measures

  1. changes in the maximum watts generated [Baseline and 12 weeks after]

    Cardiopulmonary exercise test will be performed as maximal test

  2. changes in (oxygen consumption) VO2 max [Baseline and 12 weeks after]

    Cardiopulmonary exercise test will be performed as maximal test

  3. changes in peak VO2 [Baseline and 12 weeks after]

    Cardiopulmonary exercise test will be performed as maximal test

  4. changes in the diaphragmatic path [Baseline and 12 weeks after]

    Diaphragm echocardiography will be performed

  5. changes in diaphragm thickness [Baseline and 12 weeks after]

    Diaphragm echocardiography will be performed

  6. changes in diaphragmatic shortening [Baseline and 12 weeks after]

    Diaphragm echocardiography will be performed

  7. changes in dyspnea [Baseline and 12 weeks after]

    Measured with mMRC scale (scores from 0-4)

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Men and women ≥18 years

  • Patients discharged from the Pulmonology Service with a diagnosis of COVID-19 by positive PCR and with severe pneumonia.

  • At least three months after the presence of at least one of the following criteria:

  1. MRC dyspnea greater than or equal to 2.

  2. Decrease in the meters walked with respect to the reference values in the 6-minute walking test.

  1. Decreased respiratory muscle strength measured at Maximum Inspiratory Pressure (PIM) and / or Maximum Expiratory Pressure (PEM) with respect to reference values.
  • Sign informed consent from the study
Exclusion Criteria:
  • Patients who do not want to be included in the study.

  • Pregnant women.

  • Impossibility to perform ergometry or ultrasound.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Josep Trueta University Hospital Girona Spain 17007

Sponsors and Collaborators

  • Institut d'Investigació Biomèdica de Girona Dr. Josep Trueta

Investigators

  • Principal Investigator: Gerard Muñoz, PhD, Girona Biomedical Research Institute

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Gerard Muñoz, Principal Investigator. PhD, PT, Institut d'Investigació Biomèdica de Girona Dr. Josep Trueta
ClinicalTrials.gov Identifier:
NCT05307562
Other Study ID Numbers:
  • COVFIS2021
First Posted:
Apr 1, 2022
Last Update Posted:
Apr 1, 2022
Last Verified:
Mar 1, 2022
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Gerard Muñoz, Principal Investigator. PhD, PT, Institut d'Investigació Biomèdica de Girona Dr. Josep Trueta
Additional relevant MeSH terms:

Study Results

No Results Posted as of Apr 1, 2022